Antimicrobial peptides: natural or synthetic defense peptides against HBV and HCV infections

According to the literature, treatment of HCV and HBV infections faces challenges due to problems such as the emergence of drug-resistant mutants, the high cost of treatment, and the side effects of current antiviral therapy. Antimicrobial peptides (AMPs), a group of small peptides, are a part of th...

Full description

Saved in:
Bibliographic Details
Published in:Virusdisease 2022-12, Vol.33 (4), p.445-455
Main Authors: Keikha, Masoud, Kamali, Hossein, Ghazvini, Kiarash, Karbalaei, Mohsen
Format: Article
Language:English
Subjects:
adjuvants
Antimicrobial peptides
Antiviral activity
Antiviral agents
Biochemistry
Biomedical and Life Sciences
Casein
cathelicidins
Cell Biology
Cell lines
Defensins
Drug resistance
Hepatocytes
Hepcidin
humans
hydrophilicity
Hydrophobicity
Immune response
immune system
Immunosuppressive agents
Intracellular
Kinases
Lactoferrin
Life Sciences
Liver cancer
Microbiology
Packaging
Protein Structure
Resistant mutant
Review
Review Article
scorpion venoms
Synthetic peptides
therapeutics
Toxicity
Venom
virus replication
Viruses
water solubility
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:According to the literature, treatment of HCV and HBV infections faces challenges due to problems such as the emergence of drug-resistant mutants, the high cost of treatment, and the side effects of current antiviral therapy. Antimicrobial peptides (AMPs), a group of small peptides, are a part of the immune system and are considered as an alternative treatment for microbial infections. These peptides are water-soluble with amphiphilic (hydrophilic and hydrophobic surfaces) characteristics. AMPs are produced by a wide range of organisms including both prokaryotic and eukaryotic cells. The antiviral mechanisms of AMPs include inhibiting virus entry, inhibiting intracellular virus replication, inhibiting intracellular viral packaging, and inducing immune responses. In addition, AMPs are a new generation of antiviral biomolecules that have very low toxicity for human host cells, particularly liver cell lines. AMPs can be considered as one of the most important strategies for developing new adjuvant drugs in the treatment of HBV and HCV infections. In the present study, several groups of AMPs (with a net positive charge) such as Human cathelicidin, Claudin-1, Defensins, Hepcidin, Lactoferrin, Casein, Plectasin, Micrococcin P1, Scorpion venom, and Synthetic peptides were reviewed with antiviral properties against HBV and HCV.
ISSN:2347-3584
2347-3517
DOI:10.1007/s13337-022-00790-y